Jim Simons
CMPX icon

Jim Simons’s Compass Therapeutics CMPX Stock Holding History

Jim Simons’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-79,000
Closed -$277K – 3299
2025
Q3 		$277K Sell
79,000
-145,600
-65% -$460K ﹤0.01% 3033
2025
Q2 		$584K Sell
224,600
-96,900
-30% -$200K ﹤0.01% 2759
2025
Q1 		$611K Buy
321,500
+42,900
+15% +$114K ﹤0.01% 2659
2024
Q4 		$404K Buy
278,600
+56,000
+25% +$93K ﹤0.01% 2947
2024
Q3 		$410K Buy
222,600
+82,000
+58% +$102K ﹤0.01% 2865
2024
Q2 		$141K Buy
140,600
+70,200
+100% +$103K ﹤0.01% 3119
2024
Q1 		$139K Sell
70,400
-106,399
-60% -$184K ﹤0.01% 3302
2023
Q4 		$276K Buy
176,799
+149,999
+560% +$260K ﹤0.01% 3016
2023
Q3 		$53K Buy
+26,800
New +$66.3K ﹤0.01% 3392
2023
Q2 		– Sell
-52,300
Closed -$171K – 3958
2023
Q1 		$171K Buy
52,300
+400
+0.8% +$1.57K ﹤0.01% 3336
2022
Q4 		$261K Sell
51,900
-12,315
-19% -$49.1K ﹤0.01% 3291
2022
Q3 		$146K Sell
64,215
-1,950
-3% -$5.4K ﹤0.01% 3487
2022
Q2 		$175K Buy
66,165
+52,865
+397% +$115K ﹤0.01% 3697
2022
Q1 		$18K Buy
+13,300
New +$27.5K ﹤0.01% 4011

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jim Simons's CMPX Position: Q4 2025 in Review

Jim Simons sold out of Compass Therapeutics (CMPX) in Q4 2025, closing a stake of 79,000 shares — an estimated $277K sold.

Jim Simons first reported a position in CMPX in Q1 2022 and held it in 14 quarters. The position peaked at $611K in Q1 2025. 173 funds tracked by Wall St. Rank hold CMPX as of Q4 2025.

  • Jim Simons reported no remaining Compass Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jim Simons sold 79,000 Compass Therapeutics shares in Q4 2025, an estimated $277K.
  • Jim Simons first reported a position in Compass Therapeutics in Q1 2022 and held it in 14 quarters.
  • Jim Simons's Compass Therapeutics position peaked at $611K in Q1 2025.
  • 173 funds tracked by Wall St. Rank held Compass Therapeutics as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.